Key Highlights

  • Evolent reported second-quarter 2026 Revenue of $652.5 million, up 47% year over year, narrowing its net loss to $28.4 million.
  • Adjusted EBITDA declined to $28.1 million from $37.5 million, as the medical expense ratio rose sharply.
  • Management raised full-year 2026 revenue guidance to $2.6-$2.7 billion and set adjusted EBITDA guidance at $120-$135 million.
  • EVH shares dropped as investors focused on the Margin compression from elevated specialty-care costs.

Evolent Health, Inc. (NYSE:EVH), a company that partners with health plans and providers to manage specialty care through value-based arrangements, delivered rapid revenue growth and raised its full-year outlook, yet its shares dropped as investors focused on the margin pressure from rising medical costs. The tension in the story is real growth set against a profitability squeeze that has now shown up clearly in the stock.

Evolent's model puts it at risk for the cost of managing specialty conditions such as oncology and cardiology for its partners' members, in exchange for fees and shared savings. When it prices and manages that risk well, the model scales attractively; when medical costs run hotter than expected, margins compress, exactly the dynamic playing out in its recent results.

Latest developments

In its second-quarter 2026 results, Evolent reported total revenue of $652.5 million, up 47% year over year, and narrowed its net loss to $28.4 million from $51.1 million a year earlier. Adjusted EBITDA, however, declined to $28.1 million (a 4.3% margin) from $37.5 million, reflecting elevated specialty-care costs; the medical expense ratio rose sharply. Management raised full-year 2026 revenue guidance to $2.6 to $2.7 billion and set adjusted EBITDA guidance at $120 to $135 million.

Evolent also announced a major oncology Partnership expected to launch by December 2026 and generate roughly $300 million in annualized revenue, covering about 1.5 million lives across Medicaid and Medicare in 11 states, pending regulatory approval.

Financial and Business position

Evolent's growth is being driven by expanding membership and new partnerships, with Performance Suite membership in the millions of lives. The key tension is that revenue growth has outpaced profitability as medical costs have risen, so the Investment case hinges on whether the company can reprice contracts and manage utilization to restore margins.

Stock-market context

EVH dropped as investors weighed the margin compression against the raised revenue outlook. The stock carries a strong-buy rating in the underlying data, reflecting optimism that the raised outlook and new partnerships point to a re-rating once margins stabilize; the cautionary case, reflected in the day's decline, is that persistent cost Inflation in specialty care could keep pressuring profitability despite strong top-line momentum.

What investors should watch

Investors may focus on the medical expense ratio and adjusted EBITDA margin trends, evidence that contract repricing is taking hold, the launch and ramp of the new oncology partnership, and membership growth across the Performance Suite.

Growth That Needs Margin to Catch Up

Evolent's model sits at the center of one of health care's biggest structural shifts, the move toward value-based care, in which providers and specialized managers take on Financial Risk for outcomes rather than being paid per service. The investment case now turns on Evolent's ability to price and manage risk accurately over time; if it can reprice contracts and stabilize costs, the current margin pressure that drove the stock lower could prove cyclical rather than structural.